SSA
BLRX

Schonfeld Strategic Advisors’s BioLineRX BLRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-355
Closed -$13K – 2607
2022
Q3 		$13K Sell
355
-5
-1% -$285 ﹤0.01% 2726
2022
Q2 		$19K Sell
360
-5
-1% -$278 ﹤0.01% 2294
2022
Q1 		$24K Buy
365
+45
+14% +$3.13K ﹤0.01% 2384
2021
Q4 		$26K Buy
320
+17
+6% +$1.77K ﹤0.01% 1977
2021
Q3 		$33K Buy
+303
New +$35.9K ﹤0.01% 2022
2021
Q2 		– Sell
-1,913
Closed -$213K – 1950
2021
Q1 		$213K Buy
1,913
+1,025
+115% +$123K ﹤0.01% 1473
2020
Q4 		$90K Buy
+888
New +$77.6K ﹤0.01% 1462

Other funds holding BLRX

ACM
Altium Capital Management New York $42M AUM
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Schonfeld Strategic Advisors's BLRX Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of BioLineRX (BLRX) in Q4 2022, closing a stake of 355 shares — an estimated $13K sold.

Schonfeld Strategic Advisors first reported a position in BLRX in Q4 2020 and held it in 7 quarters. The position peaked at $213K in Q1 2021. 18 funds tracked by Wall St. Rank hold BLRX as of Q4 2022.

  • Schonfeld Strategic Advisors reported no remaining BioLineRX position as of Q4 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 355 BioLineRX shares in Q4 2022, an estimated $13K.
  • Schonfeld Strategic Advisors first reported a position in BioLineRX in Q4 2020 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's BioLineRX position peaked at $213K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held BioLineRX as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.